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Pathway to NCI Designation

“ … The purpose
of National
Cancer Institute
(NCI)‑Designated
Cancer Centers
is to capitalize on
all institutional
cancer research
capabilities, integrating
meritorious programs
in laboratory, clinical,
and population
research into a single
transdisciplinary
research enterprise
across all institutional
boundaries … .”

The Paragraph to the left is taken from the Reviewer’s
Orientation Manual, the guide NCI reviewers such as
myself use to evaluate the accomplishments of cancer
centers seeking NCI-designation. A common shorter
translation of it is, “the whole is greater than the sum of
the parts.” For a new cancer center like ours, with high
aspirations to become an NCI-designated cancer center
within a decade, “re:align” better reflects what we have
been doing since my arrival at George Washington
University (GW) a little more than two years ago.
Together with the senior leaders of the GW School
of Medicine and Health Sciences (SMHS) and its clinical
partners, the GW Medical Faculty Associates (MFA),
GW Hospital, and the Milken Institute School of Public
Health at GW, we are breaking down old silos and aligning all cancer-related initiatives
(laboratory, clinical, and population research) into one cohesive entity: the GW Cancer
Center. This decision to invest significant time and capital in the fight against cancer is
critically important for Washington, D.C., a community that continues to rank among the
nation’s leaders in the incidence of and mortality from numerous cancer types.
The GW Cancer Center team has worked diligently to align existing cancer programs
and many talented faculty members and administrators from GW’s Foggy Bottom campus,
as well as from our affiliated institution, Children’s National Health System, and paired them
with strategic new recruits in an effort to create an innovative cancer center in the city and
the surrounding metropolitan region. So far, we have recruited more than 20 faculty members from prestigious academic institutions nationwide to join the GW Cancer Center.
Our alignment and growth has to be strategic; as such, we are building upon our existing clinical and scientific strengths, and we are tailoring them to fill gaps in cancer care and
research in the region. We have identified four basic science programs — cancer biology
(genetics and epigenetics), cancer immunology and immunotherapy, microbial oncology,
and cancer engineering — and one population sciences program (cancer prevention and
policy) that have the greatest relevance and impact to our community, and we are investing
significant effort and resources to make them hallmarks of the GW Cancer Center portfolio. We are also bolstering clinical programs that empower our patients from diagnosis to
treatment and, ultimately, to survivorship. To achieve these goals, we are looking outside
our campus boundaries for guidance, and therefore we have selected an external advisory
board composed of NCI-designated cancer center directors and leaders in the specialties
where we want to achieve national prominence. Internally, we have established a governance committee, which includes the dean of SMHS, the CEO of GW Hospital, and the president and CEO of the MFA that helped us in making this alignment smooth and effective.
In the pages of this edition, titled re:align, you can read about our plans to earn an
NCI designation; our emphasis on lymphoma research and treatment through the use
of cutting-edge immunotherapeutic approaches, such as CAR T-cell therapy; our efforts
to address access-to-care issues and other health policy concerns; and our programs to
improve quality of life for our cancer patients in active treatment and beyond.
On a personal note, the vision we outlined in our first edition, re:imagine, is becoming
a reality, and this edition, re:align, is a proof that with your support and commitment, we
can make “the whole greater than the sum of the parts” at GW Cancer Center.

EDUARDO SOTOMAYOR, MD
Director, George Washington
University Cancer Center
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ALIGNING ON LYMPHOMA CARE
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Kieron Dunleavy, MD, is
the inaugural leader of
the GW Cancer Center’s
lymphoma team. The team will
bring experts together from
different specialties to grow and
advance GW’s lymphoma care
and research offerings.
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GW Cancer Center
Receives Avon Grant
The George Washington University (GW) Cancer Center received
a $100,000 check from the Avon
Foundation for Women at the 15th
Annual Avon 39 The Walk to End
Breast Cancer in May. Accepting the
check on behalf of the GW Cancer
Center was Mandi Pratt-Chapman,
MA, associate center director for
patient-centered initiatives and
health equity.
The money will be used to fund
a patient navigator who will break
down barriers and provide resources
to help 300 breast cancer patients
in the D.C. area. The program will
also include a new Spanish-speaking
support group for women living with
breast cancer.
“Avon’s continued support of our
patient navigators provides help for
so many women in the area,” said
Pratt-Chapman. “Patient navigators
are crucial resources for women, especially in a fragmented health care
system, as they begin and continue
their fight against breast cancer.”

Armored
for Life
In July, the George
Washington University (GW) Cancer Center
teamed with the ArmorUp
Campaign for an event
at the Katzen Cancer
Research Center infusion
center. Patients received
workout gear and encouragement to take on
cancer through physical
fitness before, during, and
after cancer treatments.

GW Researcher Receives $1.2 Million Grant
to Standardize Cancer Genomics Data
RAJA MAZUMDER, PhD, ASSOCIATE
PROFESSOR of biochemistry and

molecular medicine at the George
Washington University (GW) School
of Medicine and Health Sciences, recently received a $1.2 million grant
from the National Cancer Institute of
the National Institutes of Health in support of a three-year project, titled “Integration of Comprehensive Cancer
Mutation and Expression-Associated
Data for Biomarker Evaluation and
Discovery,” to collect and standardize
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the wide array of cancer research data
available in the scientific community.
“There is a lot of data already generated, and that data is growing exponentially,” said Mazumder. “Projects
like this one will make utilizing that
data much easier for researchers.”
Mazumder and his research team
are developing two databases,
BioMuta and BioXpress. The team
will pull the data into a framework,
standardize cancer terms to ensure
that they are mapped correctly, and

provide interfaces and applications
that allow users to easily access
the data.
“This project will allow for connecting cancer genomics mutation and expression data within an
evolutionary context,” said Mazumder. “The primary outcome will be
that users of BioMuta and BioXpress
will be able to identify high priority
experimental targets for biomarker
discovery for diagnostics, therapeutics, and prognostics.”

IN BRIEF

Study Finds Genetic Variations May Offer
a Strategy for Reducing Breast Cancer Incidence
Researchers at the George Washington University
(GW) exploring the genomic data from women
with a genetic risk for breast cancer, who may
never develop cancer, found their cancerfree state may be related to a second genetic variation. Looking at data of women
with BRCA 1/2 genetic mutations, GW
scientists discovered that some women
also had a co-occurrence of a rare COMT
genetic variant.
“Not all mutation carriers develop the
disease, and the underlying reasons for this
should be looked at, particularly with the large
data sets now available to researchers,” said Anelia Horvath, PhD, senior author for the study and associate research professor of pharmacology and physiology

Patricia Berg
Selected
as AAAS Fellow
The American Association for
the Advancement of Science (AAAS)
named Patricia Berg, PhD, professor of biochemistry and molecular
medicine at the George Washington
University School of Medicine and
Health Sciences, a fellow of the AAAS.
Berg was selected for her “important contributions to cancer research
with the discovery of BP1 protein,
activated in 80 percent of breast
cancers and 70 percent of prostate
cancers,” according to the AAAS.
Berg also discovered that the
presence of BP1 protein increases as
breast cancer progresses from normal tissue to aggressive breast cancer. BP1 is associated with increased
cell growth, resistance to drugs, and
metastasis. Moreover, BP1 protein
can control other genes, including
several oncogenes known to cause
breast cancer. Her work has had a
dramatic effect on cancer research.

at the GW School of Medicine and Health Sciences.
The study, titled “Co-Occurrence of COMT and
BRCA 1/2 Variants in a Population” and published in the New England Journal of Medicine, outlines a strategy for exploring similar genetic mutations.
“We do not claim the variant is preventative of breast cancer in BRCA 1/2
carriers; further research is needed to
make those claims,” said Horvath. “What
we have done is illustrate a strategy for
looking at the many data sets available for
scientists today to look at different genes,
different mutations, and discover patterns for
why someone may never develop the disease predisposed by their high-risk mutation.”

Pounding the Pavement
for Cancer Patients
For eight consecutive years the George Washington University Cancer Center has partnered with the Marine Corps Marathon (MCM). GW
Cancer Center hosted a team of marathon and 10k runners for the 42nd
Annual race through Washington, D.C., and Arlington, Virginia, Oct. 22.
Money raised through this charitable partnership goes to help cancer
patients across the D.C.-metropolitan area, and supports the GW Cancer
Center’s mission to drive innovative research, personalized care, and
cancer policy in the nation’s capital.
For more information about the GW Cancer Center MCM teams,
email gwcimcm@gwu.edu.

The George Washington University Cancer Center
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Edward Seto, PhD, Installed as
King Fahd Professor of Cancer Biology
INSTALLATION HIGHLIGHTS LONG-STANDING RELATIONSHIP BETWEEN SAUDI ARABIA AND GW
FOR EDWARD SETO, PhD, ASSOCIATE

center director for basic sciences at
the George Washington University
(GW) Cancer Center and professor
of biochemistry and molecular medicine at the GW School of Medicine
and Health Sciences, the key to a long
career in cancer research is simple:
“Rather than try to know everything,
we should focus on how we can contribute a small piece to a large puzzle.”
Seto’s small pieces — in the form
of cancer epigenetics and histone
deacetylase enzymes, or HDACs —
have helped him chip away at finding
a cure. Basic epigenetics boils down
to “good” and “bad” genes in cells;
the bad appear in cancer cells, the
good in normal cells. HDACs can affect gene expression without altering
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DNA, and Seto, by regulating gene
expression, is working to turn off the
bad genes and bring cancer cells
back to normal cells.
“I’m honored today to be given
this opportunity to contribute … to
the GW Cancer Center, the medical
school, the university, and the educational ambitions and goals of the late
King Fahd,” said Seto at his installation as the King Fahd Professor of
Cancer Biology on Feb. 6.
King Fahd bin Abdulaziz Al Saud,
who ruled Saudi Arabia from 1982
until his death in 2005, was “somebody who cared very much about
education,” according to his nephew,
Abdullah Al-Saud, ambassador to the
United States at the Royal Embassy
of Saudi Arabia. King Fahd served as
minister of education from 1954 to

1960, and he helped lay the foundation for a nationwide school system.
“I’m very happy to be part of
the celebration of something that
somebody I knew was behind,” said
Al-Saud, after accepting a framed
medallion commemorating the
installation.
Saudi Arabia and GW, under King
Fahd’s leadership, began combining efforts in education in the 1990s,
and the relationship has continued to
grow, culminating in the installation.
With that support, Seto is prepared to follow another life lesson:
“As a scientist, you must follow your
results and data, trust your instincts,
stay on your path, but be prepared
for unexpected turns. Keep going
until you find it, and don’t let anyone
discourage you.”

IN BRIEF

On the Road to
Cancer Prevention
In 1995, local nonprofit organization the Prevent Cancer Foundation conducted a needs assessment
of the Washington, D.C., community
and determined that women in the
region, particularly in medically underserved neighborhoods, were not
getting screened for breast cancer.
The city, they determined, had many
gaps in access to mammography services, and a mobile mammography
program, such as a “mammovan,”
might help close those gaps.
“The barriers to screening, particularly in terms of transportation,
prevented women from getting to
a mammography facility,” recalls

Carolyn “Bo” Aldigé, president and
founder of the Prevent Cancer Foundation. Insurance and cost, she adds,
are other key problems. “We wanted
to start a program where women
could get screened, free-of-charge.”
The foundation put the call out
for partners and, after evaluating all
of the proposals, chose the George
Washington University (GW). “Together, we founded The GW Medical
Faculty Associates Mobile Mammography Program, and we’ve been
partners in it ever since,” she says.
From that initial partnership has
grown a relationship of more than 20
years, and in that time, the Alexandria,

The Skinny on
Sun Exposure

Virginia-based nonprofit has provided
more than $4 million in support for
the university’s cancer programs.
“Our mission,” explains Aldigé, “is
saving lives through cancer prevention and early detection. It’s very
important to fund research, support
education, and provide community
outreach, which to us means meeting
the needs of the medically underserved — the uninsured and underinsured. Sometimes that means taking
your programs to where the people
in need are in the community.”
Each year since that initial grant
to create the GW Mammovan, the
Prevent Cancer Foundation has
awarded grants to GW to support
the program and keep it rolling to
communities in need of screening. In
2005, the Prevent Cancer Foundation
provided another large grant to fund
the purchase of a replacement van.
That support has increased access to
mammography services throughout
Washington, D.C., providing care to
more than 2,000 women annually.
“We are very proud of this 20-year
association. We feel the need is still
there, and this has grown into a program that women in the community
really trust and rely on. It’s been a
great partnership,” says Aldigé. “We
have always felt that GW plays an
important role in the community.”

Each year since the initial
grant to create the GW
Mammovan, the Prevent
Cancer Foundation has
awarded grants to GW to
support the program.

An international survey on
sun exposure behaviors and
skin cancer detection found
there are many imperfections
and geographic inequalities in
prevention of skin cancer.
Information from the study,
published in the Journal of the
European Academy of Dermatology & Venereology by researchers from La Roche-Posay and the
George Washington University
(GW) Department of Dermatology, could help inform future
awareness campaigns developed
to address the need to reduce
the incidence of skin cancer.
With nearly 20,000 participants around the world, it was
one of the largest international
studies of its kind on consumer
sun protection and behaviors.
Survey results indicated that 88
percent of respondents were
aware of the risks of developing
skin cancer when exposed to the
sun without protection. However,
four in 10 respondents said they
don’t think to protect themselves
from the sun outside of vacation.
“This is a global wake-up call,”
says Adam Friedman, MD, senior
author for the study and associate professor of dermatology at
the GW School of Medicine and
Health Sciences. “There are still
a lot of gaps in people not only
actively monitoring for cancer,
but also preventing it.”
According to the data, using
sunscreen and wearing sunglasses were the most frequent preventive measures. Education level, as
well as gender, influenced the degree of sun protection: A higher
level of education corresponded
to a higher level of sun protection.

The George Washington University Cancer Center
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Aligning on
Lymphoma Care
BY KATHERINE DVORAK

“It’s an opportune time to build something new in lymphoma,” says Kieron Dunleavy,

“I want to
understand what
the needs are in
D.C. and really
address those
in a unique way
that has not been
done before.”
KIERON DUNLEAVY, MD

MD, inaugural leader of the George Washington University (GW) Cancer Center’s lymphoma team. The GW Cancer Center is doing just that — bringing experts together from
different specialties to create world-class lymphoma care offerings.
Dunleavy will draw upon support from GW Cancer Center Director Eduardo Sotomayor, MD, and Mitchell Smith, MD, PhD, associate center director for clinical investigations at the GW Cancer Center, to grow and advance GW’s lymphoma care and research
offerings.
One major component is a synergy between
the GW Cancer Center and Children’s National
Health System (Children’s National), which is
opening the door to cutting-edge treatments.
Researchers at Children’s National pioneered
novel cell-based cancer therapies for patients
with Epstein-Barr virus (EBV)-associated lymphomas, as well as more recently for patients
with Hodgkin’s disease and non-Hodgkin’s lymphoma that are not EBV associated, says Catherine Bollard, MD, director of the Program for
Cell Enhancement and Technologies for Immunotherapy at Children’s National and professor
of pediatrics and of microbiology, immunology,
and tropical medicine at the GW School of MedBRINGING EXPERTS TOGETHER
icine and Health Sciences (SMHS).
FOR WORLD-CLASS CARE
Children’s National currently treats lymphoKieron Dunleavy, MD (right), is the inauma patients with CAR T-cells, immune system
gural leader of the GW University Cancer
Center’s lymphoma team. The team will
cells that are genetically engineered to kill canbring experts together from different
cer. Even adult lymphoma patients seek care at
specialties to grow and advance GW’s
Children’s National, Bollard says. However, the
lymphoma care and research offerings.
new collaboration will allow adult patients to receive care at the GW Cancer Center through an
extension of the Children’s National cell therapy program, she notes.
“It’s an incredibly exciting time for the field of immunotherapy,” Bollard says. “To be
able to extend more into the adult cancer space is very exciting. I think with the unique
talent at GW [Cancer Center], this synergizes extremely well with … where we should be
going in the lymphoma field.”

The George Washington University Cancer Center
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Lymphoma
Facts >>
>> There are two forms of
lymphoma: Hodgkin’s
lymphoma and non-Hodgkin’s lymphoma. With
Hodgkin’s lymphoma,
cancer cells make up just
a small number of the
cells in a cancerous lymph
node, while the rest of the
cells are normal immune
cells. In non-Hodgkin’s
lymphoma, cancer cells
make up most of a tumor.
Hodgkin’s and non-Hodgkin’s lymphoma also differ
in the way they spread and
in how they are treated.
>> Non-Hodgkin’s lymphoma
is one of the most common cancers in men and
women. It accounts for
about 4 percent of all cancer in the United States,
according to the American
Cancer Society.
>> About 72,240 people in
the United States will be
told they have non-Hodgkin’s lymphoma in 2017,
according to the American
Cancer Society.
>> People with cancer who
have difficulty eating or
a loss of appetite during
treatment should, according to the National Cancer
Institute, eat small and
frequent meals, avoid
foods low in calories and
protein, try high-calorie,
high-protein drinks when
not hungry, eat foods at
room temperature, and
avoid spicy foods.
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That expertise will help the GW Cancer Center attract patients and new clinical trials, adds Smith. “We will have things here that nobody else has because of the partnership with Children’s [National],” he says. “They’re really a world-class program in cellular
immunotherapy.”
In addition to the expertise from Children’s National, Dunleavy brings his own prowess
in lymphoma research to GW after years of working in the field at the National Cancer
Institute. Dunleavy says his major research interest is in diffuse large B-cell lymphoma, an
aggressive form of lymphoma that can arise in lymph nodes, the gastrointestinal tract, the
skin, the brain, or bone, among other locations. As the lymphoma offerings build up, he
says he’ll continue his research here.
Another key focus, Dunleavy adds, will be lymphomas that mainly impact people in
their teens and 20s. Areas of research will include Burkitt lymphoma, in which cancer
starts in immune cells called B-cells, and mediastinal large B-cell lymphoma.
These patients’ lymphomas “are unique. If you look at their molecular biology, it’s different from that of children and adults,” Dunleavy says. “This suggests that there is a need
to study AYA [adolescent and young adult] lymphoma in specific clinical trials.”
Dunleavy says the GW Cancer Center and Children’s National will be able to work together to better serve that group, especially by building local
studies geared toward that patient population.
The clinical partner institutions could create a
model for the rest of the country as young lymphoma patients shift to adult care, Dunleavy points out.
“I think GW and Children’s National is a great platform to have this transition go well, to have the adult
lymphoma doctors talk with the children lymphoma
doctors, and to embark on new research.”
Dunleavy says that paying attention to lymphoma
issues in Washington, D.C., will be top of mind for
his team.
TWO TYPES OF LYMPHOMA
“GW is a fantastic place because it has such a
There are two forms of lymphoma:
strong public health school [the Milken Institute
Hodgkin’s and non-Hodgkin’s. With
School of Public Health] and a strong infectious disHodgkin’s lymphoma, cancer cells
ease program,” Dunleavy says. “I want to understand
make up just a small number of the
what the needs are in D.C. and really address those
cells in a cancerous lymph node. In
in a unique way that has not been done before.”
non-Hodgkin’s lymphoma, cancer
Another component is the Cutaneous Lymphocells make up most of a tumor.
ma Multidisciplinary Clinic, established by Frank
Glass, MD, professor of dermatology and pathology
at SMHS.
The clinic aligns a variety of specialties for the care of patients with these disorders,
Glass says. “You need a lot of resources to take care of these patients. So we’ll have dermatology, hematology/oncology, hematopathology, and radiation … because the disease has many different clinical presentations,” he explains.
Glass notes that the clinic will offer patients “virtually every level of diagnostics and
treatment modalities.” These will include skin-directed creams, chemotherapy, phototherapy, light therapy, and radiation.
In addition to the larger treatment offering, Glass says the clinic will work to reach out
to patients in the community to sign them up for clinical trials.
That community outreach will extend to physicians in and around Washington, D.C.
as well. “We’ll interface with community physicians, not only so they can recommend patients for clinical trials, but also to help with follow-up and continuity of care,” Glass says.
“Our skills and training are particularly conducive for the interdisciplinary approach,”
he adds. “A lot of places are missing the key components of the team that make this system work, but we have that.”

Mitchell Smith:
Paving the Way for
Cutting-Edge Clinical Trials
BY KATHERINE DVORAK

REACHING OUT TO UNDERSERVED COMMUNITIES
Mitchell Smith, MD, PhD, is the associate center director for
clinical investigations at the GW Cancer Center. In that role,
Smith oversees all cancer clinical trials. He also works to
enhance trust in the community in order to grow participation in the trials the center runs, making a concerted effort
to reach out to people living in underserved communities.

Sitting in his new office on the eighth floor of the Science and
Engineering Hall, Mitchell Smith, MD, PhD, associate center director
for clinical investigations at the George Washington University (GW)
Cancer Center, lays out his vision for a center that pioneers new treatments, rapidly delivers them to patients, and continually engages
with the community it serves.
“It’s always been the goal to take good care of patients, but now
we want to be on the cutting edge in terms of research and providing access to new drugs for patients,” he says. “Ultimately, [we want
to] take science that’s developed here, in the medical school and the
laboratories … to our patients.”
In his role, Smith oversees all cancer clinical trials. He sees the GW
Cancer Center becoming a hive of activity, opening new trials at a fast
clip, while developing a strong focus on in-house science.
Smith also works to enhance trust in the community in order to
grow participation in the trials the center runs. It’s the GW Cancer
Center’s job to reach out to people living in underserved communities, and educate those residents, he says. “We’ll talk to people
who know the community, to learn how to reach residents and show
them that the best treatment is often [provided in] a clinical trial,”
Smith says.
For much of his career, Smith concentrated on blood cancers, such
as leukemia and lymphoma. He comes to GW from Cleveland Clinic’s
Taussig Cancer Institute, where he served as director of the lymphoid
malignancy program. Prior to that, Smith held the role of director for
the lymphoma program at Fox Chase Cancer Center in Philadelphia.
Smith says coming to GW is an exciting opportunity, adding he
couldn’t turn down the chance to build up the clinical investigations
division of a new and evolving cancer center.
“You don’t always have a chance to get in on the ground floor with
people you respect and trust,” he adds, noting that he knows GW
Cancer Center Director Eduardo M. Sotomayor, MD, from his years in
the lymphoma field. “This is a new challenge … I bring certain expertise, but I have a lot of learning to do.”

The George Washington University Cancer Center
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Pathway to NCI Designation
BY CAROLINE TRENT-GURBUZ

The tagline for the National Cancer
Institute (NCI) Cancer Centers Program
— “The whole is greater than the sum of
the parts” — couldn’t be more apt for the
George Washington University (GW) Cancer Center as it seeks a prestigious NCI
designation.
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The goal, according to Michael Benedict, PharmD, associate center director for
administration and finance at the GW Cancer Center, is to bring together the best
minds across departments, the university,
and the research community to create a
competitive, high-quality cancer center

worthy of the designation. Benedict and
Eduardo M. Sotomayor, MD, director of
the GW Cancer Center, have long been in
the business of NCI designations — Benedict on the planning and administration
side, Sotomayor on the programming and
reviewing side — and with their experience,
they’ve crafted a five-year plan to reach
that target.

Building Blocks
The designation is “first and foremost a
grant,” Benedict explains. “It’s something
we have to apply for, and it’s very competitive — there are a limited number of these
types of centers in the country.”
Currently, there are just 69 NCI-designated cancer centers spread across 35
states and the District of Columbia. Each
one, Benedict adds, has a different model,
though all are built on six essential characteristics: a focus on cancer research, a demonstration of institutional commitment, a
center director with the appropriate qualifications and authorities, transdisciplinary
collaborations, suitable physical space, and
organizational capabilities that allow for
and facilitate the advancement of science.
“We’re beginning to assemble the
building blocks,” Benedict says, pointing
to the six essential characteristics as the
framework guiding his and Sotomayor’s
plan. “We’re now going through and creating scientific themes that will roll into programs for the cancer center.”
Those themes, with additional subprojects, are designed to help the center
“find [its] own niche,” Sotomayor says. “I
think by doing that, we’re going to have
a very good chance down the road to get
NCI designation, so we need to be very
strategic in our efforts.”
The first, a hot topic among researchers, is cancer immunology and immunotherapy, which involves the investigation
of the immune system’s role in cancer development and treatment.
The second, a microbiology oncology
program (see page 14 for more details)
that builds on the strengths of the SMHS
Department of Microbiology, Immunology, and Tropical Medicine, links campus
scientists who are studying virus-initiated

cancers, the influence of the microbiome,
and the role of endogenous retroviruses.
The third theme, cancer biology, is a
basic science program that “looks at the
genetics of cancer, how the control of
cell growth goes awry,” Benedict says,
while a fourth, which continues to evolve,
examines cancer through the lens of engineering. That particular prong also incorporates faculty from the School of Engineering and Applied Sciences into the
fight against cancer, a key collaboration
that highlights the GW Cancer Center’s
overall aim of fostering a cross-disciplinary
research community.
“We’re also recruiting scientists to fill
unique needs,” Benedict says, “and we’re
linking laboratory scientists with clinical investigators so that we can translate scientific discoveries to our patients and have our
patient experience inform the laboratory.”
Finally, the GW Cancer Center will focus
on clinical and population-based research,
“where our science interfaces with our patient care and the community we serve,”
says Benedict.

The Application Process
Once Benedict and Sotomayor have established the scientific themes and the essential characteristics, they will package
those into an application and submit it to
the NCI, most likely in 2021 or 2022.
The post-submission process includes
a peer-review system where nationally
known scientific leaders evaluate the GW
Cancer Center for the NCI. “If you have
shown impact and you score high enough,
you might receive the designation,” Benedict says.
In addition to the coveted NCI designation, a successful submission will also earn
the GW Cancer Center a $1 million grant to
support further development of the center’s infrastructure and shared resources.
What’s key, Benedict says, is guidance
and advice. The GW Cancer Center team,
for instance, is using an external advisory
board (EAB), made up of members from
other cancer centers across the country. “The EAB helps keep us on track and
makes sure we maintain the focus of creating an impact on [cancer],” says Sotomayor.

“We’re recruiting
scientists to fill
unique needs,
and we’re linking
laboratory
scientists
with clinical
investigators
so that we can
translate scientific
discoveries to
our patients.”
MICHAEL BENEDICT, PharmD

The George Washington University Cancer Center
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“They will tell us when they think we are
ready to make an application.”
Likewise, Benedict and Sotomayor will
meet with NCI members, who will weigh in
on the best time to submit an application.
Each NCI designation lasts for five years,
and a different set of centers are under
review three times per year. So, Benedict
explains, timing can be critical; if the team
is planning to submit during the same period as older, larger, and more established
centers, there could be fewer resources
available, and there may be a recommendation to wait for the next review.

The Impact
While the designation itself is prestigious,
and $1 million is always useful, the benefits
of an NCI cancer center extend far beyond
the potential funding.

“The designation will help draw patients,
it gives our faculty increased reputations,
it enables us to recruit better scientists,”
Benedict says. “It really changes the culture of what we’ve got here.”
The designation also drives economic
development. As scientists, recruited to
join the center, move to the District, they
bring with them teams of people, who subsequently invest in the area.
Most importantly, however, the NCI
designation — and the research that comes
with it — translates to better patient care.
“We take care of patients differently and
better in NCI cancer centers than elsewhere,” Benedict says. “It’s the same concept that transcends the laboratory side to
the patient care side, where we’re organizing people around the diseases and patients. The care is different and enhanced.”

NCI Designated Cancer Centers
WA

4%

Just 4 percent of the roughly 1,500
cancer centers in the United States
are recognized as Comprehensive
Cancer Centers, Cancer Centers,
or Basic Laboratory Centers

OR
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Comprehensive Centers meet NCI standards in six essential characteristics:
>> focus on cancer research
>> demonstration of institutional commitment
>> qualified center director
>> transdisciplinary collaborations
>> suitable physical space
>> organizational capabilities to facilitate the advancement of science

*Data from the National
Cancer Institute website, nci.org

A Policy of Improving Access to Care
BY STEVE GOLDSTEIN

The George Washington University (GW) Cancer Center is a bit like a toddler who

PATIENT-CENTERED INITIATIVES
Mandi Pratt-Chapman, MA, associate center director of the GW
Cancer Center, is the force behind
the center’s patient-centered
initiatives and health equity.

“It should not be
for the patient
to have to shop
around and piece
together the care
they need.”
MANDI PRATT-CHAPMAN, MA

is ready to run soon after mastering the walk. Less than two years after its founding, GW
Cancer Center is reshaping the care landscape in Washington, D.C. One of its most significant achievements to date is radical improvement in access to cancer care for Medicaid
beneficiaries who, officials say, have had to cope with delayed and fragmented service
care across a variety of health care providers and systems.
The initiative was led by Associate Center Director Mandi Pratt-Chapman, MA, the
dynamo behind patient-centered initiatives and health equity at the GW Cancer Center.
“Dr. Sotomayor [director of the GW Cancer Center] wants us to have a policy presence
given our unique location in the nation’s capital,” she explains. “We have resources to put
together a larger policy portfolio, but for now the focus is on the Medicaid project.”
Pratt-Chapman has held a series leadership positions in the cancer community and
was the driving force behind GW’s rise to national prominence in survivorship and patient-centered initiatives. Even before she arrived at GW, Pratt-Chapman was aware of
access to care issues in the District of Columbia, and says she’d been hearing “that there
were few oncologists who would take Medicaid patients.” This was all very confusing from
the patient’s perspective. “It should not be for the patient to have to shop around and
piece together the care they need,” she says. “If you have a cancer diagnosis it should be
easier to access the care you need.”
Pratt-Chapman works with the assistance of Claudia Schlosberg, Medicaid director at
the D.C. Department of Health Care Finance, bringing stakeholders together as part of
a policy, systems, and environmental (PSE) change effort to improve access to the continuum of cancer care services for Medicaid beneficiaries.
GW Cancer Center discovered that the reason providers were not participating in the
Medicaid network was that chemotherapy reimbursement was largely compensated by
Medicaid below the drug acquisition cost. A push was made to adjust drug reimbursement to match Medicare reimbursement. “Sharing data and information, and having
frank discussions led to policy changes to address these access barriers,” says Schlosberg. “There’s been a significant improvement of Medicaid operations.”
Aiding in the effort was Sara Rosenbaum, JD, the Harold and Jane Hirsh Professor
of Health Law and Policy at the Milken Institute School of Public Health at GW. “I provided additional information to Mandi about the D.C. program and also participated in
the meetings with Claudia,” says Rosenbaum, adding that she shared the view that the
program as structured did not do enough to make medical oncology services accessible.
“Now, drugs are available in more medical oncology locations and more doctors are seeing more medical oncology patients covered by Medicaid,” she explains.
Asked why this disparity in access remained unresolved for so long, Schlosberg said
that since she became Medicaid director in 2014, “my priorities have been to advance the
creation of enduring systems to ensure the Medicaid program operates efficiently, effectively, and in the best interest of District residents. This means identifying, and, wherever
possible, eliminating barriers to access and improving quality.”
Rosenbaum says that other policy initiatives are being considered. “Mandi and I have
talked about other things that could be done — such as better survivorship programs,
better outreach programs,” says Rosenbaum. Pratt-Chapman notes that there is huge
potential “in having some of the nation’s best policy experts at GW.”

The George Washington University Cancer Center
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A CONFLUENCE

OF SCIENCE
BY CAROLINE TRENT-GURBUZ
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It was easy to put it together, recalls
Eduardo M. Sotomayor, MD, director
of the George Washington University
(GW) Cancer Center.
“All the ingredients are here. Our job
was to put them together to prepare a
nice meal,” he says. “I’m confident because we have good science, so we’ll
be able to move the field forward.”
The meal is microbial oncology, and
with each course of the meal comes an
expert chef, starting with Douglas Nixon, MD, PhD, chair of the Department of
Microbiology, Immunology, and Tropical Medicine and Walter G. Ross Professor of Basic Science Research at GW
School of Medicine and Health Sciences
AN INTERDISCIPLINARY APPROACH
(SMHS), and newcomer Kieron DunDouglas Nixon, MD, PhD, chair of
leavy, MD, who joined the team in April
the Department of Microbiology,
from the National Cancer Institute (NCI).
Immunology, and Tropical Medicine
and Walter G. Ross Professor of Basic
As Sotomayor explains, microbial
Science Research at SMHS, is examinoncology — or the study of how miing the impact of human endogenous
crobes, such as viruses, bacteria, or
retroviruses on certain types of cancers
parasites, can be manipulated to fight
with a $2.2 million NCI grant.
cancer — boils down to the immune system. “These days, we have the technology to modify immune cells or microbes to fight cancer,” Sotomayor says.
One modified immune cell, known as a chimeric antigen receptor (CAR)
T-cell, is particularly effective against lymphomas and some types of leukemia. “These days, we have also learned that what we call ‘inflamed’ cancers
are the ones more likely to respond to novel immunotherapeutic approaches,” he adds. In these kinds of cancer, the body has an inflammatory reaction, and the immune cells are subsequently more receptive to treatment.
Non-inflamed cancers, or those with an absence of inflammation, are harder
to treat. That’s where microbes come in.

The George Washington University Cancer Center
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Microbes have the unique ability to travel to hard-to-reach areas of the
body, such as the pancreas, gallbladder, or prostate, that tend to exhibit
“non-inflamed” features. Some microbes are also multicellular organisms
that have circulatory and secretory systems, and they can be modified
to produce biological agents to potentially fight cancer. Additionally, researchers can use anti-microbial therapies that can easily kill the “therapeutic microbes,” Sotomayor says, to prevent harming the host.
“By using these microbes … we [might be able to] convert non-inflammatory tumors into more inflammatory ones,” Sotomayor explains, adding that
it makes treatment easier and more effective.
Using genetically modified, or transgenic, parasites to both convert tumors and deliver cancer therapy is an important goal of the microbial oncology program, but researchers have other significant goals as well. The
program also prioritizes the influence of intestinal or
skin microbiota on cancer development and therapy — a
rapidly evolving field that links microbial composition in
compartments such as the gastrointestinal (GI) tract with
the development of GI malignancies. Rounding out the
innovative program is the study of retrovirus-related malignancies and the broader role of human endogenous
retroviruses (HERVs) in immuno-oncology. That’s the area
in which Nixon’s talent lies.
With a $2.2 million NCI grant, Nixon, alongside GW
collaborators, is examining how HERVs impact certain
types of cancers. HERVs, he explains, are ancestral remnants of past viruses, which infected ancient humans,
non-human primates, and other species, becoming integrated into DNA. These ancient viruses have remained
in modern human DNA, passing from mother to child.
Nixon’s research team has long published studies on the
BIOLOGICAL AGENTS FIGHTING CANCER
effect of HIV infection on HERVs, and has found there may
Microbial oncology is the study of how
also be a link between HIV and cancer.
microbes, such as viruses, bacteria, or
“It appears that breast and prostate cancer are found
parasites, can be manipulated to fight cancer.
less frequently in HIV-infected people than in the genMicrobes have the unique ability to travel
eral population,” Nixon says. “That is a puzzle, because
to hard-to-reach areas of the body, such as
we think of HIV infection as being associated with people
the pancreas, gallbladder, or prostate. Some
having more cancer. That is true for cancers such as anal
microbes are also multicellular organisms
cancer, but it seems strange to have a virus infection like
that have circulatory and secretory systems,
HIV, which appears to, in some senses, protect against
and they can be modified to produce
biological agents to potentially fight cancer.
prostate or breast cancer.”
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Nixon had already discovered that HIV wakes up some
of the transcriptionally silent HERVs; therefore, it might
be possible that in patients with HIV, the newly activated HERVs stimulate an immune response, which surveils
prostate and breast cancer cells that could be expressing
the same HERVs. To test this hypothesis, Nixon, in collaboration with Matthew Bendall, a PhD rotation student, and
Keith Crandall, PhD, director of the GW Computational
Biology Institute at the Milken Institute School of Public
Health at GW, developed “Telescope,” a computational
pathway program designed to determine which HERVs
are expressed in prostate, breast, and colon cancers, in
patients with and without HIV.
“This is really a brand-new tool, which we think will be
incredibly valuable in looking for expression of these endogenous retroviruses in a number of different disease
With a $2.2 million NCI grant,
categories, including in cancer,” Nixon says.
Like Nixon, Dunleavy is building his microbial oncolNixon, alongside GW collaborators,
ogy research on past experience in HIV. “I’ve got a backis examining how human
ground in developing treatments for HIV-associated
lymphomas, and we thought at GW it would be very interendogenous retroviruses impact
esting to have a microbial oncology program where we
certain types of cancers.
not only look at HIV, but also look at … other organisms
and viruses that may contribute to lymphomas,” he says.
As the field progresses, Dunleavy explains, researchers are developing
a better appreciation of the role viruses can play in cancer. Sotomayor is
building the mission of the GW Cancer Center around that development.
“The lessons we are learning from immunology and infectious disease
are driving the knowledge that we are uncovering in cancer immunology,”
he says. “As we learn how the immune system fights infection, at the molecular level, all the lessons we learn from that can be applied to harnessing
the immune system to fight cancer.”
Right now, Sotomayor, with team members such as Nixon and Dunleavy,
is building the GW Cancer Center’s clinical research infrastructure, but his
ambitions — he’d like to see ideas translated to the clinic within five years
— hinge on his instincts about cancer. “There is a confluence of [using] immunology against infectious diseases and immunology against cancer, and
I think in the future, we’re going to see there is a closer link between these
two fields than we thought,” he says. “That’s the reason that bringing together these experts makes a lot of sense.”

The George Washington University Cancer Center
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COMPLEMENTS
TO CARE
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BY THOMAS KOHOUT | PHOTOGRAPHS BY SUSAN GENDRON

Breast cancer is one of the leading forms of cancer facing the country, with more than

THE HEALING TOUCH
Reiki is a traditional Japanese technique using
specific hand positions
on or near a patient’s
body. Through gentle
yet methodical healing
touch, the Reiki therapist
can direct energy into the
patient to activate the
natural healing processes
of the patient’s body
and restore physical and
emotional well-being.

250,000 new cases diagnosed each year, according to the Centers for Disease Control. Although
the incidence of breast cancer has dropped annually since 2000, Washington, D.C., still has one
of the highest rates in the country. To combat this ongoing problem, the George Washington
University (GW) Comprehensive Breast Center (Breast Care Center), supported by clinical partners the GW Medical Faculty Associates, GW Hospital, and the GW Cancer Center, has grown
to become one of the area’s leading breast cancer programs. GW’s nationally accredited center
offers multidisciplinary services for early detection, diagnosis, and treatment of breast cancer using advanced technologies to help breast cancer patients navigate their way through diagnosis,
treatment, and survivorship.
For nearly a decade, the Breast Care Center has bolstered its gold-standard clinical care by
offering a one-time complementary medicine clinic each month. The clinic serves as a sampler
for many of the integrative care options available such as physical therapy (PT), therapeutic massage, Reiki, acupuncture, and naturopathic consultation.
“[The clinics] allow us to provide a more holistic approach to patient care,” says Christine Teal,
MD, chief of the Division of Breast Care, associate professor of surgery at GW School of Medicine
and Health Sciences, and director of GW’s Breast Care Center.
Treatments for breast cancer can take a toll on patients. Side
effects such as pain, fatigue, or depression are common, but
often slip past conventional medical therapies. Complementary medicine can sometimes offer patients relief where traditional medicine leaves off.
For patients, such as Shaunique Pierre, the free clinic offers
a welcome opportunity to sample some of the holistic offerings available and address some of the lingering side effects
of treatment.
“My arms weren’t going over my head without some discomfort, and I had lost sensation in my upper arm,” explains
Pierre, who was having mobility issues in her shoulder area
following reconstructive surgery. “The PTs do an amazing job,
they handle everything. Now the sensation is starting to come back.”
It’s nice, says Teal, “when we are doing this complementary clinic, for patients to be seen by a
PT as well,” adding that, while physical therapy is covered under most insurance plans and Breast
Care Center patients use the PT services through the hospital, the extra session is well received.
Teal attributes her interest in complementary medicine to a moment early in her career when
her best friend was diagnosed with breast cancer. During treatment, Teal’s friend explored complementary medical treatments that were far more common and
accepted in her Colorado home. Her experience sparked Teal’s
ABOUT THE PHOTOGRAPHER
curiosity.
Susan Gendron is an award-winning photographer and gradu“I just loved the holistic approach,” she recalls. “Herbs that
ate of the University of New
helped during chemotherapy, things that helped reduce neuropHampshire with a BA in studio
athy, it was a unique emphasis on well-being and how to make
art with a concentration in phoyourself feel better while going through a more conventional
tography. She is self-taught in
treatment plan. I hoped that someday I could provide those kinds
digital shooting, darkroom, and
of services to my patients.
archival printing techniques.
“I think most physicians these days are open to complementary
She is also a breast cancer
medicine
practices,” Teal adds, stressing that these services are
survivor and credits her good
called complementary medicine for a reason; they aren’t alternahealth to the care she received
tives to conventional treatment protocols. “It’s always in addition
from the physicians, nurses, and
to standard treatment. [Complementary medicine] is just trying to
staff of the George Washington
University (GW) Medical Faculty
find a way to get patients through standard treatment feeling a
Associates and the GW Hospital.
little bit better.”
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FINDING THE RIGHT DIET
Naturopathic consultation
enables patients to discuss
nutritional approaches to
their cancer treatments, such
as special diets and nutritional supplements. These
therapies range from following a basic, healthy vegetable-based diet to adopting
highly restrictive diets and
supplement regimens.
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STRENGHTENING THE BODY
Physical approaches,
such as exercise, progressive deep relaxation,
massage, chiropractic
or osteopathic therapies, among others,
are designed to relax,
align, energize, and
strengthen the body.

ACUPUNCTURE FOR
GREATER WELL-BEING
Acupuncture is a centuries-old
Chinese medicine that uses
hair-like needles to stimulate
key points along the nervous
system. Proponents believe
this stimulation sparks a biochemical response that can be
used to treat nausea or pain
and promote greater physical
and emotional well-being.

The George Washington University Cancer Center
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A Poodle
Among
Patients
BY CAROLINE TRENT-GURBUZ
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“He loves people, and he’s calm.
He’s the perfect therapy dog.”
AMY KAPLAN

Every Wednesday, James the poodle — occasionally sporting thematic wear, be it a
cowboy hat, colorful bandana, or pumpkin costume — and his owner, Sandra Johnson, visit the Infusion Center at the George Washington University (GW) Cancer Center. James’
presence is met with pats and rhetorical queries of “who’s a good boy?” by patients and
staff members alike.
On this particular Wednesday, James is warmly greeted by Jennifer Bires, LICSW, a
former clinical social worker at the GW Cancer Center, before he clicks through the door
to the patients receiving doses of chemotherapy.
The pet therapy program, Bires says, was started by Jamie Glidewell, a social work
intern at the GW Medical Faculty Associates, a year ago. “She worked in hospice before
she came here and started a pet therapy program there.
She saw how beneficial it was,” Bires explains. “[All of the
patients] look forward to seeing James. It’s a really great
break in their long time being here; it’s a reprieve from
what’s going on.”
For patient Amy Kaplan, who has her own dog, 13-yearold Lulu, seeing James “is a highlight, that’s for sure.”
“He loves people, and he’s calm,” she says, reaching
down from her reclined chair to rub James’ back. “He’s the
perfect therapy dog.”
James is newly certified, not quite a year into his new
role. The idea to transition the almost 7-year-old poodle
from pet to therapy dog sparked after Johnson, a native
of Orlando, Florida, read coverage of the June 2016 nightclub shooting in her hometown.
“This group was sending therapy dogs to Florida to
help with the grieving of all those families, and something
about the article caught my attention,” she recalls. “I decided to look up the therapy dog group [Therapy Dogs
International]. I thought, ‘You know what, this is perfect
timing; this is meant to be. I’m going to sign him up and
get registered.’”
After a temperament evaluation, James was registered, and Johnson scouted out potential clinics. The GW
Cancer Center was the first place she called, and the response was immediate. “We set it up to start coming every
Wednesday,” she says. “James really likes it.”
Although he isn’t the only therapy dog who visits patients at the GW Cancer Center, James is the most regular
one. “There are days you can tell people are really happy to see him,” Johnson says. “He’s not a big kisser; he
doesn’t really give out a lot of them. But sometimes he’s really kissing somebody and
giving them lots of love, and you can tell that he’s really helped some people, taken their
mind off things.”
Patient Taylor Ferrell agrees that James always makes him feel better. “You could bring
him every day. That would make me happy.”

PUPPY LOVE
GW’s pet therapy program was
started a year ago by Jamie Glidewell, a former social work intern
at the GW Medical Faculty Associates. Of the therapy dogs who visit
patients at the GW Cancer Center,
James the Poodle, pictured
here, is the most regular one.
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SUPPORT GROUPS
The George Washington University Cancer Center with support provided by the Dr. Cyrus and Myrtle
Katzen Cancer Research Center (Katzen Center) supports a wide variety of holistic and wellness services
for cancer patients and their families. These groups are free of charge and open to the community.

THE GW MEDICAL
FACULTY ASSOCIATES
(GW MFA)
2150 Pennsylvania Ave., N.W.
Washington, D.C. 20037
ACTIVE TREATMENT
(all cancers)
Open to patients currently in treatment.
Registration required.
Second and Fourth Wednesday
each month, 12:30–1:30 pm
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
ADVANCED BREAST
CANCER GROUP
Open to patients with stage IV
breast cancer. Registration required.
Fourth Tuesday of each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
BRAIN TUMOR SUPPORT GROUP
Open to brain tumor survivors/patients
and caregivers.
Registration required.
First Tuesday of each month,
6–7:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
CAREGIVERS’ SUPPORT GROUP
Open to caregivers of those diagnosed
with cancer to share common concerns,
give and receive advice, and learn
coping skills. Registration required.
Third Tuesday each month,
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
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GENTLE YOGA
This group introduces patients
and caregivers to the physical and
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,
Fifth floor activities room
800 21st St., N.W.
Facilitator: Yael Flusberg
eruiz@mfa.gwu.edu
202-677-6228
HEAD AND NECK CANCER GROUP
For patients, survivors, and caregivers
of head and neck cancers. Registration
required.
First Tuesday each month,
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
KIDS’ CLUB
For families with kids (ages 6–12)
in which a parent or sibling is in
treatment or is a survivor.
Fourth Wednesday each month,
6–7:30 p.m.
Smith Center for Healing and the Arts
1632 U St., N.W.
Facilitators: Erin Price and
Lauren Broschak
202-483-8600
MULTIPLE MYELOMA GROUP
This group is open to multiple myeloma
patients/survivors and caregivers.
Registration required.
Third Tuesday each month,
5:30–6:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
NUTRITION CLUB
First Monday each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Jennifer Leon
202-741-6489

PROSTATE CANCER
EDUCATIONAL GROUP
The prostate cancer educational group
is free and open to patients and
survivors in the Washington, D.C., area.
Registration required.
Second Tuesday each month,
6–7 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak
lbroschak@mfa.gwu.edu
202-677-6229
SURVIVORSHIP SERIES
An educational series featuring a
different speaker each month.
Second Thursday each month,
11:45 a.m.–12:45 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak
lbroschak@mfa.gwu.edu
202-677-6229
YOUNG ADULT GROUP
Young adults (19 to 39 years of age)
who are currently in treatment or are
cancer survivors.
Third Sunday of each month,
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St, NW
Facilitator: Jennifer Bires
202-483-8600
Parking is validated for all groups
at the GW Cancer Center. For
more information about upcoming
support groups and events, visit

smhs.gwu.edu/katzencancer/events.

Executive
Committee
Jeffrey S. Akman, MD ’81, RESD
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of Administrative Medicine, and
dean, the George Washington
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Comprehensive Cancer Center /
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Stephen B. Gruber, MD, PhD,
MPH, director of the University
of Southern California Norris
Comprehensive Cancer Center
Helen Heslop, MD, PhD,
director, Center for Cell and Gene
Therapy, Baylor University
Robert DiPaola, MD, dean,
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College of Medicine
Marcy Waldinger, MS, former
chief administrative officer,
University of Michigan

Solutions for the Skin
Cancer treatments induce a host

SUPPORTIVE
ONCODERMATOLOGY
The Supportive Oncodermatology
Clinic, launched in part thanks
to support from La Roche-Posay,
will support cancer patients and
survivors who suffer from the
persistent side effects of cancer
treatments, as well as provide
diligent skin cancer surveillance.

of side effects, but among the most
distressing can be dermatological:
hair loss, extremely dry skin and rashes, infections, painful nail conditions.
Some patients turn away from treatment altogether, while others simply
battle through. Adam Friedman, MD,
associate professor of dermatology
at the George Washington University
(GW) School of Medicine and Health
Sciences, however, believes he has a
potential solution.
A new Supportive Oncodermatology Clinic, falling under the umbrella of
the GW Cancer Center and within the
oncodermatology program, is designed as a one-stop shop for patients.

The clinic, which currently operates on
a monthly basis, serves as a resource
for both oncologists and their patients,
while prioritizing survivorship and increasing knowledge of the burgeoning
supportive oncodermatology field.
“This is somewhat unique … there
are only a handful of other institutions
across the country that offer a clinic
that addresses the well-established
and, for the most part, expected side
effects to many if not all of the cancer
therapies that are life-saving but also
come with some significant baggage,”
Friedman says.
The side effects, he adds, can
range from chemotherapy-induced
alopecia, or hair loss, to xerosis, severely dry skin that can cause fissures
in the hands and feet that are “exquisitely painful and hard to heal.”
What’s critical is seeing patients in
the clinic early, when they can receive
preventive medication to possibly
limit side effects, as well as during
and after cancer treatment. “A lot of
the skin, hair, and nail side effects
we see can often persist well beyond
the time when treatment has ended,”
Friedman explains. “Plus, having a history of any type of cancer increases
your risk for skin cancer. So these
patients need a different level of surveillance, a different level of care than
someone who has not undergone
treatment for cancer.”
In addition to monitoring patients’
progress, Friedman also catalogues
any new side effects and potential
treatments. Patients in treatment at the
GW Cancer Center, he adds, may have
their oncologist or nurse contact the
oncodermatology scheduling appointment team to set up a visit to the clinic,
while those receiving treatment outside
of GW may contact the Department of
Dermatology and request to be seen
by an oncodermatologist.

The side effects of cancer treatments can range from chemotherapy-induced alopecia,
or hair loss, to xerosis, severely dry skin that can cause fissures in the hands and feet.

The George Washington University Cancer Center

25

THE GEORGE WASHINGTON UNIVERSITY
School of Medicine and Health Sciences
2600 Virginia Ave, NW
Suite 329
Washington, D.C. 20037

NON-PROFIT ORG
U.S. POSTAGE
PAID
Merrifield, VA
PERMIT NO. 2657

